TY  - JOUR
AU  - Gadgeel, Shirish
AU  - Goss, Glenwood
AU  - Soria, Jean-Charles
AU  - Felip, Enriqueta
AU  - Georgoulias, Vassilis
AU  - Lu, Shun
AU  - Cobo, Manuel
AU  - Syrigos, Konstantinos
AU  - Lee, Ki Hyeong
AU  - Goker, Erdem
AU  - Guclu, Salih Z
AU  - Isla, Dolores
AU  - Morabito, Alessandro
AU  - Dupuis, Nicholas
AU  - Buhnemann, Claudia
AU  - Kramer, Nicole
AU  - Solca, Flavio
AU  - Ehrnrooth, Eva
AU  - Ardizzoni, Andrea
PY  - 2017
DO  - 10.1016/j.lungcan.2017.05.010
UR  - http://hdl.handle.net/10668/11269
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after first-line chemotherapy. In this study, the ability of the...
LA  - en
PB  - Elsevier
KW  - Afatinib
KW  - Biomarker
KW  - Erlotinib
KW  - LUX-lung 8
KW  - Squamous cell carcinoma of the lung
KW  - VeriStrat
KW  - Afatinib
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Blood Proteins
KW  - Carcinoma, Squamous Cell
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Hematologic Tests
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Predictive Value of Tests
KW  - Quinazolines
KW  - Retrospective Studies
KW  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
KW  - Survival Analysis
KW  - Treatment Outcome
TI  - Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
TY  - research article
VL  - 109
ER  -